Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × alectinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 3 Neoplasms 2 Lung Neoplasms 2 Urinary Bladder Neoplasms 1 Solid Tumors 1 Rare Tumour 1 Rare Tumor 1 Hematologic Neoplasms 1 Genomic Instability 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Bevacizumab 190 Fluorouracil 184 Oxaliplatin 177 Irinotecan 177 Leucovorin 165 Capecitabine 126 Cetuximab 119 Panitumumab 58 Folfox protocol 40 regorafenib 35 Radiotherapy 35 IFL protocol 33 pembrolizumab 32 HMPL-013 29 Nivolumab 26 trifluridine tipiracil drug combination 25 Neoadjuvant Therapy 23 Drug Therapy 20 Celecoxib 16 tislelizumab 15 aflibercept 14 XELOX 14 sintilimab 13 Trifluridine 13 Trastuzumab 13 Gemcitabine 13 Chemotherapy, Adjuvant 13 durvalumab 12 Floxuridine 12 atezolizumab 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05725200 2023-02-21

EVIDENT

Oslo University Hospital

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡